Contract Drug Manufacturing under cGMP

What this entry covers

FDA’s current good manufacturing practice (CGMP) regulations, including 21 CFR Parts 210 and 211, set minimum requirements for the methods, facilities and controls used to make drugs. They apply to contract manufacturers as well as product owners, and FDA’s 2016 guidance on quality agreements describes how the two parties should define their CGMP responsibilities.

MyRHC indexes this framework so practitioners, auditors, and automated agents can find the authoritative primary sources in one place. This page is a navigation aid, not legal advice, and is not a substitute for the official text.

Official documentation

• Primary official source: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
• FDA guidance, Contract Manufacturing Arrangements for Drugs: Quality Agreements (November 2016): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/contract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry

How to use this index entry

1. Open the official link above (or the agency home if the deep link drifts).
2. Confirm the edition or revision date against your program scope.
3. Map applicability by sector and jurisdiction listed in the metadata.
4. Follow related frameworks only after checking their own official sources.

Disclaimers

• MyRHC does not host proprietary standards text (ISO, some industry bodies).
• Where standards are paywalled, we link to the publisher’s catalog page.
• Always verify current requirements with counsel and the issuing authority.